We are live on
!
Find out more
SM
Sabby Management Portfolio holdings
AUM
$111M
1-Year Est. Return
74.4%
This Fund
S&P 500
This Quarter
Est. Return
-34.3%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$115M
AUM Growth
+$792K
(+0.69%)
Cap. Flow
+$10.1M
Cap. Flow
% of AUM
8.76%
Top 10 Holdings %
Top 10 Hldgs %
83.12%
Holding
142
New
32
Increased
15
Reduced
32
Closed
53
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Recon Technology
RCON
|
+$5M |
| 2 |
GMVD
G Medical Innovations Holdings Ltd. Ordinary Shares
GMVD
|
+$3.87M |
| 3 |
BETS
Bit Brother Limited Class A Ordinary Shares
BETS
|
+$2.24M |
| 4 |
CN Energy Group
CNEY
|
+$2.19M |
| 5 |
NMTR
9 Meters Biopharma
NMTR
|
+$2.08M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nuvectis Pharma
NVCT
|
+$4.41M |
| 2 |
TBLT
ToughBuilt Industries, Inc. Common Stock
TBLT
|
+$2.28M |
| 3 |
iShares Russell 2000 ETF
IWM
|
+$1.92M |
| 4 |
BGXX
Bright Green Corporation Common Stock
BGXX
|
+$1.49M |
| 5 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.34M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 77.64% |
| 2 | Healthcare | 10.03% |
| 3 | Technology | 3.2% |
| 4 | Consumer Discretionary | 2.1% |
| 5 | Communication Services | 1.53% |
Similar funds
IWA
BFA
WPWM
BCM
ZS
KC
FI
CIM
Sabby Management's Q1 2023 Portfolio in Review
As of Q1 2023, Sabby Management held 142 positions worth $115M, up 0.69% from $114M the previous quarter. Its ten largest holdings account for 83% of the portfolio.
Sabby Management deployed $10.1M of net new capital in Q1 2023, opening 32 new positions and adding to 15 existing holdings. Its largest new stake was Recon Technology: 1,097 shares worth $1.35M.
By sector, the portfolio is most concentrated in Miscellaneous at 78% of assets, up from 71% a quarter earlier, followed by Healthcare and Technology.
On the sell side, the largest reduction was Cocrystal Pharma, an estimated $792K trimmed.
- Sabby Management's largest Q1 2023 buy was Recon Technology: 1,097 shares worth $1.35M.
- Sabby Management added most to Akari Therapeutics in Q1 2023, an estimated $1.68M increase.
- Sabby Management's biggest Q1 2023 reduction was Cocrystal Pharma, cutting an estimated $792K.
- Sabby Management fully exited Nuvectis Pharma in Q1 2023, selling an estimated $4.41M.
- Sabby Management's ten largest holdings make up 83% of its $115M portfolio in Q1 2023.
- Sabby Management opened 32 new positions and closed 53 in Q1 2023.
- Sabby Management's portfolio value rose 0.69% quarter-over-quarter to $115M.
Based on Sabby Management's 13F filing for Q1 2023, filed 15 May 2023.